These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30809871)

  • 1. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
    Meng L; Huang J; Jia Y; Huang H; Qiu F; Sun S
    Int J Clin Pract; 2019 May; 73(5):e13331. PubMed ID: 30809871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency.
    Bennett AC; Bennett CL; Witherspoon BJ; Knopf KB
    Expert Opin Drug Saf; 2019 Nov; 18(11):1055-1063. PubMed ID: 31500468
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.
    Arabyat RM; Raisch DW; McKoy JM; Bennett CL
    Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population-based propensity score-matched cohort study.
    Garg M; Venugopalan V; Vouri SM; Diaby V; Iovine NM; Park H
    Pharmacotherapy; 2023 Sep; 43(9):883-893. PubMed ID: 37381584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case-control study.
    Son N; Choi E; Chung SY; Han SY; Kim B
    BMC Cardiovasc Disord; 2022 Feb; 22(1):44. PubMed ID: 35152888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone.
    Lee CC; Lee MT; Chen YS; Lee SH; Chen YS; Chen SC; Chang SC
    JAMA Intern Med; 2015 Nov; 175(11):1839-47. PubMed ID: 26436523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Fluoroquinolone Use and Hospitalization With Aortic Aneurysm or Aortic Dissection.
    Brown JP; Wing K; Leyrat C; Evans SJ; Mansfield KE; Wong AYS; Smeeth L; Galwey NW; Douglas IJ
    JAMA Cardiol; 2023 Sep; 8(9):865-870. PubMed ID: 37585175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
    Xu C; Pan L; Zhang Y; Zhang J; Sun Q; Fang W
    Int J Clin Pract; 2021 Aug; 75(8):e14273. PubMed ID: 33908133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis.
    Rawla P; El Helou ML; Vellipuram AR
    Cardiovasc Hematol Agents Med Chem; 2019; 17(1):3-10. PubMed ID: 30947680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data mining of the public version of the FDA Adverse Event Reporting System.
    Sakaeda T; Tamon A; Kadoyama K; Okuno Y
    Int J Med Sci; 2013; 10(7):796-803. PubMed ID: 23794943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).
    Xiang DC; Xie WL; Cheng GY; Yue M; Du XY; Jiang J
    Heliyon; 2024 Sep; 10(18):e37547. PubMed ID: 39309803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
    Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
    Kadoyama K; Kuwahara A; Yamamori M; Brown JB; Sakaeda T; Okuno Y
    J Exp Clin Cancer Res; 2011 Oct; 30(1):93. PubMed ID: 21970649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments.
    Miyata K; Izawa-Ishizawa Y; Tsujinaka K; Nishi H; Itokazu S; Miyata T; Kondo M; Yoshioka T; Niimura T; Aizawa F; Yagi K; Sato M; Hyodo M; Hamano H; Kawada K; Chuma M; Zamami Y; Tsuneyama K; Goda M; Ishizawa K
    Biomed Pharmacother; 2024 Oct; 179():117418. PubMed ID: 39265233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system.
    Taher MK; Alami A; Gravel CA; Tsui D; Bjerre LM; Momoli F; Mattison D; Krewski D
    Expert Opin Drug Saf; 2022 Feb; 21(2):269-276. PubMed ID: 34641748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter to the Editor: Consideration on "An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin- association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency" by Bennett et al.
    Monti M; Silimbani P; Ruscelli S; Frassineti GL
    Expert Opin Drug Saf; 2020 Aug; 19(8):1055-1056. PubMed ID: 32427001
    [No Abstract]   [Full Text] [Related]  

  • 18. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.
    Jones SC; Budnitz DS; Sorbello A; Mehta H
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1099-106. PubMed ID: 23963962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
    Kadoyama K; Miki I; Tamura T; Brown JB; Sakaeda T; Okuno Y
    Int J Med Sci; 2012; 9(1):33-9. PubMed ID: 22211087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between fluoroquinolones and aortic dissection and aortic aneurysms: a systematic review and meta-analysis.
    Wee I; Chin B; Syn N; Lee KS; Ng JJ; Choong AMTL
    Sci Rep; 2021 May; 11(1):11073. PubMed ID: 34040146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.